Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: strong financial positioning with cash runway into 2027 is positive, but increased net loss and debt facility raise concerns. Clinical trial risks, competitive pressures, and economic factors add uncertainty. The Q&A section highlights confidence in ongoing trials but lacks clarity on certain aspects, which may worry investors. The market cap suggests moderate volatility, but without clear positive catalysts, the stock price is likely to remain stable within a neutral range.
Key Financial Performance
Net Loss $68 million, an increase from $53.7 million in Q1 2024, reflecting higher operational costs as the company advances its clinical programs.
Cash, Cash Equivalents and Marketable Securities $249.4 million as of March 31, 2025, providing a strong financial foundation to support operations into 2027.
Debt Facility Entered into a $125 million debt facility with K2 HealthVentures, with $20 million available for draw this year, enhancing financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NMRA-511: Advancing Phase 1b study for Alzheimer's disease agitation, with top-line data expected by end of 2025.
Navacaprant: Progressing in Phase 3 KOASTAL program for Major Depressive Disorder (MDD), with top-line data from KOASTAL-3 expected in Q1 2026 and KOASTAL-2 in Q2 2026.
M4 PAMs: Planning to bring a best-in-class M4 PAM into the clinic by mid-2025.
Debt Facility: Entered into a $125 million debt facility with K2 HealthVentures, with $40 million available for draw this year.
Financial Position: Cash, cash equivalents, and marketable securities expected to support operations into 2027.
Clinical Execution: Focused on advancing multiple programs towards key milestones over the next 12 months.
Patient Enrollment: Implemented changes in KOASTAL studies to ensure appropriate patient enrollment.
Intellectual Property: Strong IP portfolio with worldwide rights and patents extending into the 2040s.
Financial Discipline: Maintaining diligent stewardship of capital as a core operational principle.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Risks: The company reported a net loss of $68 million for Q1 2025, an increase from $53.7 million in Q1 2024, indicating potential financial strain.
Debt Financing: Neumora entered into a $125 million debt facility with K2 HealthVentures, which may pose risks related to debt repayment and interest obligations.
Clinical Trial Risks: The company acknowledged challenges in clinical trial enrollment and patient selection, particularly in the KOASTAL studies, which could impact the success of their MDD programs.
Regulatory Risks: The need for successful outcomes in two out of three KOASTAL trials to file an NDA highlights regulatory risks associated with drug approval processes.
Market Competition: The company faces competitive pressures in the neuroscience space, particularly in developing effective treatments for brain diseases, which may affect market positioning.
Economic Factors: The overall economic environment and its impact on funding and investment in biotech could pose challenges to the company's financial stability and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Pipeline Development: Neumora is advancing an industry-leading pipeline of programs targeting novel mechanisms of action for prevalent brain diseases.
Debt Facility: Entered into a $125 million debt facility with K2 HealthVentures, with $40 million available for draw this year.
Financial Discipline: Emphasized the importance of maintaining diligent stewardship of capital.
Clinical Execution: Focused on advancing multiple programs towards key milestones over the next 12 months.
Intellectual Property: Strong IP portfolio with worldwide rights to all programs and patents extending into the 2040s.
Cash Runway: Expect cash, cash equivalents, and marketable securities, along with the $20 million from K2 facility, to support operations into 2027.
Clinical Data Milestones: Anticipate top-line data for NMRA-511 by the end of 2025, KOASTAL-3 in Q1 2026, and KOASTAL-2 in Q2 2026.
Net Loss: Reported a net loss of $68 million for Q1 2025, compared to $53.7 million for Q1 2024.
Cash Position: Ended Q1 2025 with $249.4 million in cash, cash equivalents, and marketable securities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Debt Facility: Entered into a $125 million debt facility with K2 HealthVentures, with up to $40 million available for draw this year.
Cash Position: Ended the quarter with $249.4 million in cash, cash equivalents, and marketable securities.
Funding Support: Expect cash and the $20 million drawn from the K2 facility to support operations into 2027.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have you had any sort of sense of how it has affected the pace of enrollment early going?
A:We've already seen benefits from steps that we've taken with both SAFER and the Verified Clinical Trial screening database that we've implemented in the K2 and K3 studies.
Q:Is it having a negative impact, in terms of the pace of enrollment?
A:The rate of those patients being excluded is consistent with our expectation. It doesn't impact our timing guidance that we provided with respect to the enrollment.
Q:Can you provide any details, in terms of sort of limitations on prepayment for K2 financing?
A:The details of the facility are disclosed in our 10-Q, but really, with this facility, what we're looking to achieve in this financing was extending our cash runway into 2027.
Q:Is the $20 million needed to get you into 2027?
A:Correct. Our existing cash balance sheet as of the March, plus the $20 million funded at close gets our runway into 2027.
Q:Could you talk about the patient population who might have received an antidepressant in KOASTAL?
A:We are ensuring the proper patients being included in K2 and K3 after the pause, with steps taken to assess patients' history.
Q:Are there any possibility of some form of an interim analysis in K2 and K3?
A:We do not have plans for an interim analysis and we are moving ahead with the enrollment.
Q:What are your latest views on how to reconcile the core mechanism based on the Phase 2 data?
A:We were surprised by J&J's decision to terminate their program, but we remain confident in navacaprant.
Q:What can you tell us about the NLRP3 program?
A:NLRP3 has been a program that we've been very excited about and progressing for a while now.
Q:What do you expect to see with the 511 data set in Alzheimer's disease agitation?
A:This is a study that hasn't been powered to show statistical separation of active from placebo, but is rather a signal seeking study.
Q:What are your thoughts on differentiation between your M4 PAM candidate and emraclidine?
A:We think ensuring optimal blood brain barrier penetration is going to provide the biggest chance to show a great central effect.
Q:When might you decide to increase enrollment in KOASTAL-2 or KOASTAL-3?
A:We haven't made a decision on what that overall number will be, but we'll provide updates at the appropriate time point.
Q:How does the MADRS baseline scores compare with the severity seen in the Phase 2 study?
A:In KOASTAL-1, we're utilizing the MADRS and we are using a cutoff of 25 or higher on the MADRS consistent with the moderate to severe MDD population.
Q:What is the mix of females that you're seeing now in K2 and K3?
A:In K2, K3, we are seeing a mix that's more representative of what's historically been seen, roughly two-thirds female, one-third male.
Q:Review of Unclear Management Responses
A:Management did not provide a clear answer regarding the specific percentage of patients who had taken prior antidepressants in the KOASTAL study, nor did they clarify the aspects of the blinded data being considered for increasing enrollment in KOASTAL-2 or KOASTAL-3.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Berns
Chief Development
Clinical Trial
Development Officer
HealthVentures
KOASTAL franchise
KOASTAL patient
KOASTAL program
KOASTAL study
MDD population
Officer Chief
PAMs
Relations Communications
Results Conference
SAFER
Trial screening
Verified Clinical
afternoon
aggression
anhedonia
antagonist Alzheimer
antidepressant
anxiety
change
clinic middle
facility
foundation
goal
milestone
navacaprant
option patient
participant
pathway
patient study
publication
screening database
treatment brain
treatment option
vision
NMRA Transcript
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Positive3-30
The earnings call revealed strong financial performance, with a 25% revenue increase, a shift from net loss to net income, and improved operating margins. These positive financial metrics, despite the lack of strategic or operational updates, suggest a favorable stock price movement. The market cap indicates a potential strong reaction, but the absence of strategic guidance tempers expectations to a positive rather than strong positive outlook.
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents a mixed sentiment. While financial discipline and a strong cash position are positives, the net loss and lack of specific guidance on certain programs create uncertainty. The Q&A section highlights management's confidence in safety profiles and potential synergies, but also reveals avoidance of specific numerical guidance and partnership details. The market cap suggests moderate reaction, leading to a neutral prediction for the stock price movement.
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Unknown5-12
The earnings call reveals mixed signals: strong financial positioning with cash runway into 2027 is positive, but increased net loss and debt facility raise concerns. Clinical trial risks, competitive pressures, and economic factors add uncertainty. The Q&A section highlights confidence in ongoing trials but lacks clarity on certain aspects, which may worry investors. The market cap suggests moderate volatility, but without clear positive catalysts, the stock price is likely to remain stable within a neutral range.
Earnings call transcript: Neumora Therapeutics Q4 2024 beats EPS expectations
Unknown3-3
The earnings call reveals several concerning factors: a failed Phase III trial for navacaprant, regulatory scrutiny, and financial constraints despite reduced operating expenses. Management's vague responses in the Q&A further amplify uncertainty. Although the company maintains a strong cash position, the competitive market, clinical trial risks, and lack of guidance adjustments suggest potential negative sentiment. Given the small-cap nature of the stock, these issues are likely to result in a stock price decline in the short term.
NMRA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
